Fecal S100A12 and fecal calprotectin as noninvasive markers for inflammatory bowel disease in children

Inflammatory Bowel Diseases

Volumn 14, Issue 3, 2008, Pages 359-366

  Sidler, Marc A ^a   Leach, Steven T ^b   Day, Andrew S ^a,b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Children; Fecal calprotectin; Fecal S100A12; Inflammatory bowel disease; Screening

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CALGRANULIN; PROTEIN S 100; PROTEIN S100A12; UNCLASSIFIED DRUG;

ADOLESCENT; AGE DISTRIBUTION; ARTICLE; CHILD; CHILD HEALTH CARE; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; CROHN DISEASE; DISEASE ACTIVITY; ENDOSCOPY; ENTERITIS; ERYTHROCYTE SEDIMENTATION RATE; FECES ANALYSIS; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; THROMBOCYTE COUNT; ULCERATIVE COLITIS;

ADOLESCENT; BIOLOGICAL MARKERS; CHILD; CHILD, PRESCHOOL; DIAGNOSIS, DIFFERENTIAL; ENDOSCOPY, GASTROINTESTINAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFLAMMATORY BOWEL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; NEW SOUTH WALES; PREVALENCE; PROSPECTIVE STUDIES; S100 PROTEINS; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX;

EID: 41149109122     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20336     Document Type: Article

References (34)

1. Catto-Smith AG, Cameron D, Rerksuppaaphol SI. Increasing incidence of Crohn's disease in Victoria, Australia [abstract]. Gastroenterology. 2003;124:A515.
2. Griffiths AM. Specificities of inflammatory bowel disease in childhood. Baillieres Best Pract Res Clin Gastroenterol. 2004;18:509-523.
3. Walters TD, Critch J, Kundhal P, et al. Epidemiology of pediatric IBD in the Greater Toronto Area. J Pediatr Gastroenterol Nutr. 2004;39:S330.
4. Griffiths AM, Buller HB. Inflammatory bowel diseases. In: Walker WA, Hamilton JR, Watkins JB, et al, eds. Pediatric Gastrointestinal Disease. 3rd ed. Hamilton, Ontario, Canada: BC Decker; 2000:613-652.
5. Hyams JS, Mandel F, Ferry GD, et al. Relationship of common laboratory parameters to the activity of Crohn's disease in children. J Pediatr Gastroenterol Nutr. 1992;14:216-222.
6. Griffiths AM, Drobnies A, Soldin SJ, et al. Enteric protein loss measured by fecal alpha 1-antitrypsin clearance in the assessment of Crohn's disease activity: a study of children and adolescents. J Pediatr Gastroenterol Nutr. 1986;5:907-911.
7. Roseth AG, Aadland E, Jahnsen J, et al. Assessment of disease activity in ulcerative colitis by faecal calprotectin, a novel granulocyte marker protein. Digestion. 1997;58:176-180.
8. Roseth AG, Fagerhol MK, Aadland E, et al. Assessment of the neutrophil dominating protein calprotectin in feces. A methodologic study. Scand J Gastroenterol. 1992;27:793-798.
9. Silberer H, Kuppers B, Mickisch O, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab. 2005;51:117-126.
10. Bunn SK, Bisset WM, Main MJ, et al. Fecal calprotectin: validation as a noninvasive measure of bowel inflammation in childhood inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2001;33:14-22.
11. Canani RB, de Horatio LT, Terrin G, et al. Combined use of noninvasive tests is useful in the initial diagnostic approach to a child with suspected inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2006;42:9-15.
12. Roseth AG, Kristinsson J, Fagerhol MK, et al. Faecal calprotectin: a novel test for the diagnosis of colorectal cancer? Scand J Gastroenterol. 1993;28:1073-1076.
13. Johne B, Kronborg O, Ton HI, et al. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol. 2001;36:291-296.
14. Tibbie JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut. 1999;45:362-366.
15. Foell D, Kucharzik T, Kraft M, et al. Neutrophil derived human S100A12 (EN-RAGE) is strongly expressed during chronic active inflammatory bowel disease. Gut. 2003;52:847-853.
16. Vogl T, Propper C, Hartmann M, et al. S100A12 is expressed exclusively by granulocytes and acts independently from MRP8 and MRP14. J Biol Chem. 1999;274:25291-25296.
17. Marenholz I, Heizmann CW, Fritz G. S100 proteins in mouse and man: from evolution to function and pathology (including an update of the nomenclature). Biochem Biophys Res Commun. 2004;322:1111-1122.
18. Foell D, Seeliger S, Vogl T, et al. Expression of S100A12 (EN-RAGE) in cystic fibrosis. Thorax. 2003;58:613-617.
19. Leach ST, Yang Z, Messina I, et al. Serum and mucosal S100 proteins, calprotectin (S100A8/S100A9) and S100A12, are elevated at diagnosis in children with inflammatory bowel disease. Scand J Gastroenterol. 2007;42:1321-1331.
20. de Jong NS, Leach ST, Day AS. Fecal S100A12: a novel noninvasive marker in children with Crohn's disease. Inflamm Bowel Dis. 2006;12:566-572.
21. Ton H, Brandsnes O, Dale S, et al. Improved assay for fecal calprotectin. Clin Chim Acta. 2000;292:41-54.
22. Yang Z, Tao T, Raftery MJ, et al. Proinflammatory properties of the human S100 protein S100A12. J Leukoc Biol. 2001;69:986-994.
23. Husebye E, Ton H, Johne B. Biological variability of fecal calprotectin in patients referred for colonoscopy without colonic inflammation or neoplasm. Am J Gastroenterol. 2001;96:2683-2687.
24. Fagerberg UL, Loof L, Myrdal U, et al. Colorectal inflammation is well predicted by fecal calprotectin in children with gastrointestinal symptoms. J Pediatr Gastroenterol Nutr. 2005;40:450-455.
25. Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir. 1980;16:273-282.
26. Lugering N, Stoll R, Kucharzik T, et al. Immunohistochemical distribution and serum levels of the Ca(2+)-binding proteins MRP8, MRP14 and their heterodimeric form MRP8/14 in Crohn's disease. Digestion. 1995;56:406-414.
27. Mork G, Schjerven H, Mangschau L, et al. Proinflammatory cytokines upregulate expression of calprotectin (L1 protein, MRP-8/MRP-14) in cultured human keratinocytes. Br J Dermatol. 2003;149:484-491.
28. Brandtzaeg P, Dale I, Fagerhol MK. Distribution of a formalin-resistant myelomonocytic antigen (L1) in human tissues. I. Comparison with other leukocyte markers by paired immunofluorescence and immunoenzyme staining. Am J Clin Pathol. 1987;87:681-699.
29. Fiocchi C. Inflammatory bowel disease: etiology and pathogenesis. Gastroenterology. 1998;115:182-205.
30. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol. 1999;34:50-54.
31. Dell'Angelica EC, Schleicher CH, Santome JA. Primary structure and binding properties of calgranulin C, a novel S100-like calcium-binding protein from pig granulocytes. J Biol Chem. 1994;269:28929-28936.
32. Rugtveit J, Fagerhol MK. Age-dependent variations in fecal calprotectin concentrations in children. J Pediatr Gastroenterol Nutr. 2002;34:323-324.
33. Beattie RM, Nicholls SW, Domizio P, et al. Endoscopic assessment of the colonic response to corticosteroids in children with ulcerative colitis. J Pediatr Gastroenterol Nutr. 1996;22:373-379.
34. Ullman TA, Palmon R. The certain uncertainty of measuring disease activity in IBD. J Clin Gastroenterol. 2007;41:123-125.